Ryvu Therapeutics sums up the achievements of 2021

In 2021, Ryvu reported revenues of PLN 37.5 million, of which more than 67 percent were received grants (PLN 25.2 million), and the remainder were revenues from partnering agreements (PLN 11.2 million) and other (PLN 1.1 million).

Operating expenses, excluding non-cash costs of the incentive program, amounted to PLN 92.4 million. They mainly consisted of costs related to research and development…